An artificial intelligence-based model developed by UT Southwestern Medical Center researchers can accurately predict which kidney cancer patients will benefit from anti-angiogenic therapy, a class of treatments that’s only effective in some patients.
“Our goal was very clear from the beginning, which was to develop a user-friendly simple chat-like interface that would provide specific high-quality answers to questions that our members would bring, utilizing only our content,” said Clifford A. Hudis, CEO of the American Society of Clinical Oncology and executive vice chair of the Conquer Cancer Foundation.
